Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma

International Journal of Cancer

Volumn 128, Issue 8, 2011, Pages 1981-1988

  Paulsson, Janna ^a   Lindh, Maja Bradic ^a   Jarvius, Malin ^b   Puputti, Marjut ^c   Nistér, Monica ^a   Nupponen, Nina N ^c   Paulus, Werner ^d   Söderberg, Ola ^b   Dresemann, Gregor ^e   Von Deimling, Andreas ^f   Joensuu, Heikki ^c   Östman, Arne ^a   Hasselblatt, Martin ^d,g  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e Zentrum für Neuro Onkologie Am Ärztehaus Velen   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

hydroxyurea; IDH1; imatinib; malignant glioma; phosphorylation; platelet derived growth factor receptor alpha; prognosis; randomized trial

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; HYDROXYUREA; IMATINIB; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; FEMALE; GENE AMPLIFICATION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SEX DIFFERENCE; SURVIVAL TIME; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; GLIOBLASTOMA; HUMANS; HYDROXYUREA; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PHOSPHORYLATION; PIPERAZINES; PROGNOSIS; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; SURVIVAL RATE;

EID: 79951966257     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25528     Document Type: Article

References (40)

1. Ohgaki H, Kleihues P,. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007; 170: 1445-53. (Pubitemid 47339290)
2. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807-12.
3. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061-8.
4. Uhrbom L, Hesselager G, Ostman A, Nister M, Westermark B,. Dependence of autocrine growth factor stimulation in platelet-derived growth factor-B-induced mouse brain tumor cells. Int J Cancer 2000; 85: 398-406. (Pubitemid 30030415)
5. Lokker NA, Sullivan CM, Hollenbach SJ, Israel MA, Giese NA,. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res 2002; 62: 3729-35. (Pubitemid 34728854)
6. Kilic T, Alberta JA, Zdunek PR, Acar M, Iannarelli P, O'Reilly T, Buchdunger E, Black PM, Stiles CD,. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res 2000; 60: 5143-50.
7. Dai C, Celestino JC, Okada Y, Louis DN, Fuller GN, Holland EC,. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 2001; 15: 1913-25. (Pubitemid 32738621)
8. Hagerstrand D, Hesselager G, Achterberg S, Wickenberg Bolin U, Kowanetz M, Kastemar M, Heldin CH, Isaksson A, Nister M, Ostman A,. Characterization of an imatinib-sensitive subset of high-grade human glioma cultures. Oncogene 2006; 25: 4913-22. (Pubitemid 44201182)
9. Haberler C, Gelpi E, Marosi C, Rossler K, Birner P, Budka H, Hainfellner JA,. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy. J Neurooncol 2006; 76: 105-9. (Pubitemid 43125736)
10. Joensuu H, Puputti M, Sihto H, Tynninen O, Nupponen NN,. Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme. J Pathol 2005; 207: 224-31. (Pubitemid 41404153)
11. Capdeville R, Buchdunger E, Zimmermann J, Matter A,. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002; 1: 493-502.
12. Raymond E, Brandes AA, Dittrich C, Fumoleau P, Coudert B, Clement PM, Frenay M, Rampling R, Stupp R, Kros JM, Heinrich MC, Gorlia T, et al. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol 2008; 26: 4659-65.
13. Dresemann G,. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann Oncol 2005; 16: 1702-8. (Pubitemid 41510147)
14. Reardon DA, Egorin MJ, Quinn JA, Rich JN, Gururangan S, Vredenburgh JJ, Desjardins A, Sathornsumetee S, Provenzale JM, Herndon JE, 2nd, Dowell JM, Badruddoja MA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 2005; 23: 9359-68.
15. Dresemann G, Weller M, Rosenthal MA, Wedding U, Wagner W, Engel E, Heinrich B, Mayer-Steinacker R, Karup-Hansen A, Fluge O, Nowak A, Mehdorn M, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J Neurooncol 2010; 96: 393-402.
16. Reardon DA, Dresemann G, Taillibert S, Campone M, van den Bent M, Clement P, Blomquist E, Gordower L, Schultz H, Raizer J, Hau P, Easaw J, et al. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br J Cancer 2009; 101: 1995-2004.
17. Baselga J,. Targeting tyrosine kinases in cancer: the second wave. Science 2006; 312: 1175-8. (Pubitemid 43801135)
18. Baselga J, Rosen N,. Determinants of RASistance to anti-epidermal growth factor receptor agents. J Clin Oncol 2008; 26: 1582-4.
19. Sequist LV, Bell DW, Lynch TJ, Haber DA,. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007; 25: 587-95. (Pubitemid 350002967)
20. Ciardiello F, Tortora G,. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160-74.
21. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD,. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-34.
22. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-65.
23. Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, Byun DS, Nasser S, Arango D, Shin J, Klampfer L, Augenlicht LH, Perez-Soler R, et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 2008; 68: 1953-61. (Pubitemid 351416582)
24. Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, Arvold ND, Baumber R, Lamborn KR, Kapadia A, Malec M, Berger MS, Stokoe D,. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 2005; 97: 880-7. (Pubitemid 41417939)
25. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005; 353: 2012-24. (Pubitemid 41609094)
26. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P,. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109. (Pubitemid 47103521)
27. Nupponen NN, Paulsson J, Jeibmann A, Wrede B, Tanner M, Wolff JE, Paulus W, Ostman A, Hasselblatt M,. Platelet-derived growth factor receptor expression and amplification in choroid plexus carcinomas. Mod Pathol 2008; 21: 265-70. (Pubitemid 351304279)
28. Paulsson J, Sjoblom T, Micke P, Ponten F, Landberg G, Heldin CH, Bergh J, Brennan DJ, Jirstrom K, Ostman A,. Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol 2009; 175: 334-41.
29. Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A,. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 2009; 118: 599-601.
30. Jarvius M, Paulsson J, Weibrecht I, Leuchowius KJ, Andersson AC, Wahlby C, Gullberg M, Botling J, Sjoblom T, Markova B, Ostman A, Landegren U, et al. In situ detection of phosphorylated platelet-derived growth factor receptor beta using a generalized proximity ligation method. Mol Cell Proteomics 2007; 6: 1500-9. (Pubitemid 47506163)
31. Koos B, Paulsson J, Jarvius M, Sanchez BC, Wrede B, Mertsch S, Jeibmann A, Kruse A, Peters O, Wolff JE, Galla HJ, Soderberg O, et al. Platelet-derived growth factor receptor expression and activation in choroid plexus tumors. Am J Pathol 2009; 175: 1631-7.
32. Fleming TP, Saxena A, Clark WC, Robertson JT, Oldfield EH, Aaronson SA, Ali IU,. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 1992; 52: 4550-3.
33. Hermanson M, Funa K, Hartman M, Claesson-Welsh L, Heldin CH, Westermark B, Nister M,. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 1992; 52: 3213-9.
34. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6: 117-27. (Pubitemid 39485684)
35. Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, Camponovo A, Etienne LL, Cavalli F, Mazzucchelli L,. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007; 97: 1139-45. (Pubitemid 47587019)
36. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007; 12: 395-402. (Pubitemid 47539306)
37. Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, Westphal M, Schackert G, Simon M, Tonn JC, Heese O, Krex D, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009; 27: 5743-50.
38. Capper D, Weissert S, Balss J, Habel A, Meyer J, Jager D, Ackermann U, Tessmer C, Korshunov A, Zentgraf H, Hartmann C, von Deimling A,. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 2010; 20: 245-54.
39. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A,. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 2008; 116: 597-602.
40. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17: 98-110.